Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
Baxter
Mallinckrodt
Dow

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Etrolizumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Etrolizumab?

Etrolizumab is an investigational drug.

There have been 12 clinical trials for Etrolizumab. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Ulcer, Colitis, Ulcerative, and Colitis. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and [disabled in preview].

There are five US patents protecting this investigational drug and sixty international patents.

Recent Clinical Trials for Etrolizumab
TitleSponsorPhase
A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's DiseaseHoffmann-La RochePhase 1
A Study to Investigate the Comparability of Pharmacokinetics of Etrolizumab Administered Subcutaneously (SC) by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)Genentech, Inc.Phase 1
A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy ParticipantsGenentech, Inc.Phase 1

See all Etrolizumab clinical trials

Clinical Trial Summary for Etrolizumab

Top disease conditions for Etrolizumab
Top clinical trial sponsors for Etrolizumab

See all Etrolizumab clinical trials

US Patents for Etrolizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Etrolizumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Etrolizumab   Start Trial Methods for diagnosing and treating inflammatory bowel disease GENENTECH, INC. (South San Francisco, CA)   Start Trial
Etrolizumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Colorcon
Medtronic
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.